D-cycloserine for the treatment of ataxia in spinocerebellar degeneration.

作者信息

Ogawa Masafumi, Shigeto Hiroshi, Yamamoto Toshiyuki, Oya Yasushi, Wada Keiji, Nishikawa Toru, Kawai Mitsuru

机构信息

Department of Neurology, National Center Hospital for Mental, Nervous, and Muscular Disorders, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-higashi, Kodaira, Tokyo 187-8551, Japan.

出版信息

J Neurol Sci. 2003 Jun 15;210(1-2):53-6. doi: 10.1016/s0022-510x(03)00009-1.

DOI:10.1016/s0022-510x(03)00009-1

PMID:12736088

Abstract

We studied the effects of D-cycloserine, a partial NMDA receptor allosteric agonist, on ataxia in patients with spinocerebellar degeneration. Fifteen Japanese ataxic patients enrolled in a 14-day single-blind trial of D-cycloserine (daily oral dose of 50 mg) following a 14-day single-blind placebo phase. At the end of the D-cycloserine administration, there was a significant reduction in the posture, gait and total score of the international cooperative ataxia rating scale and in the time for walking and speech tasks. D-Cycloserine was well-tolerated and no adverse effect was observed. D-Cycloserine may have therapeutic efficacy for spinocerebellar ataxia.

摘要